Amalgamated Bank Trims Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Amalgamated Bank cut its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 38,319 shares of the medical equipment provider’s stock after selling 1,763 shares during the quarter. Amalgamated Bank’s holdings in Zimmer Biomet were worth $4,048,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. CKW Financial Group boosted its position in shares of Zimmer Biomet by 11.7% in the fourth quarter. CKW Financial Group now owns 955 shares of the medical equipment provider’s stock valued at $101,000 after acquiring an additional 100 shares during the period. FWG Holdings LLC boosted its holdings in Zimmer Biomet by 2.9% in the 3rd quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider’s stock valued at $372,000 after purchasing an additional 101 shares during the period. Romano Brothers AND Company grew its position in shares of Zimmer Biomet by 1.1% during the 4th quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider’s stock valued at $1,000,000 after purchasing an additional 102 shares in the last quarter. Financial Advocates Investment Management increased its holdings in shares of Zimmer Biomet by 3.5% in the third quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock worth $330,000 after purchasing an additional 103 shares during the period. Finally, Dakota Wealth Management raised its position in shares of Zimmer Biomet by 1.3% in the fourth quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider’s stock worth $1,016,000 after buying an additional 122 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Truist Financial restated a “hold” rating and set a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. JMP Securities restated a “market outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Raymond James decreased their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Finally, Barclays dropped their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday, February 10th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Trading Up 0.3 %

NYSE:ZBH opened at $104.32 on Friday. The firm has a market capitalization of $20.77 billion, a P/E ratio of 23.44, a P/E/G ratio of 1.95 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The company has a fifty day moving average of $105.72 and a 200 day moving average of $107.38.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter last year, the company earned $2.20 earnings per share. On average, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. Zimmer Biomet’s dividend payout ratio is presently 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.